GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7768 NBOH-2C-CN hydrochlorideSummary: 5-HT2A agonist -
B7729 DR 4485 hydrochlorideSummary: 5-HT7 antagonist -
B7723 R 1485 dihydrochlorideSummary: 5-HT6 antagonist,selective and high affinity -
B7690 Tegaserod maleateSummary: Partial agonist of 5-HT4 -
B7660 BIMU 8Summary: 5-HT4 agonist -
B7650 ST 1936 oxalateSummary: 5-HT6 receptor agonist -
B7605 MDL 100907Summary: 5-HT2A receptor antagonist -
B7583 LY 266097 hydrochlorideSummary: 5-HT2B receptor antagonist -
B7563 ZotepineSummary: 5-HT2A receptor and dopamine D2 receptor antagonist -
B7561 NPEC-caged-serotoninSummary: 5-HT receptor agonist
